Biogen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Biogen Inc. stock rises Wednesday, still underperforms market

📈 Biogen Inc. (BIIB) shares rose 2.44% to $179.90 on Wednesday as the broader stock market surged.

🤝 The S&P 500 Index SPX climbed 2.51% to reach a level of 6,782.81.

🏛️ The Dow Jones Industrial Average DJIA increased 2.85% to close at 47,909.92.

📊 This marked the second consecutive day of gains for Biogen's stock.

⚠️ Despite the intraday rise, Biogen still underperformed the overall market during the session.

🔍 Data provided by FactSet and Dow Jones supported the market tracking analysis.

ℹ️ MarketWatch Automation partnered with Automated Insights to deliver this content.

⚖️ Intraday data reflects trades reported through Nasdaq only for U.S. stock quotes.

⏱️ Historical and current end-of-day data were provided by FACTSET with at least a 15-minute delay where required.

📅 The article was published on April 8, 2026 at 5:00 p.m. ET.

© All rights reserved to MarketWatch, Inc. for the content published on this date.

Bullish Signals
  • Biogen Inc. (BIIB) shares advanced 2.44% to $179.90 on Wednesday, demonstrating positive momentum in the stock market.
  • This represents the stock's second consecutive day of gains, indicating sustained upward price movement.
Risk Factors
  • Biogen Inc. stock continues to underperform the broader market, rising only 2.44% compared to a 2.51% gain in the S&P 500 Index.
  • Despite a second consecutive day of gains for shares reaching $179.90, the stock's relative weakness suggests ongoing concerns about its competitive positioning or growth prospects.
  • The underperformance occurred during an all-around great trading session with major indices like the Dow Jones Industrial Average rising 2.85%, highlighting a disconnect between Biogen and bullish market sentiment.
Full Analysis
Shares of Biogen Inc. (BIIB) gained momentum on Wednesday, climbing 2.44% to reach $179.90 in a strong market session. The pharmaceutical company's stock marked its second consecutive day of gains, though it still trailed the broader market indices as the S&P 500 Index advanced 2.51% to close at 6,782.81 and the Dow Jones Industrial Average rose 2.85% to 47,909.92. The article highlights that despite the positive daily performance, Biogen continues to underperform relative to major market benchmarks. The news was published on April 8, 2026, at 5:00 p.m. ET by MarketWatch, Inc. The report notes that all quotes reflect local exchange time and that intraday data provided by FACTSET is delayed at least 15 minutes or according to specific exchange requirements, while historical end-of-day data is also sourced from FACTSET. All real-time last sale data referenced in the report includes only U.S. stock quotes reported through Nasdaq.